CPL-01 in the Management of Postoperative Pain After Bunionectomy (NCT05831449) | Clinical Trial Compass
CompletedPhase 3
CPL-01 in the Management of Postoperative Pain After Bunionectomy
United States616 participantsStarted 2023-05-22
Plain-language summary
Subjects receive study drug during bunionectomy and are followed for pain and opioid use, with the hypothesis that those who receive CPL-01 will have less pain and less opioid use than either control arm.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Ability to sign ICF
* Bunion for elective primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia, without collateral procedures or additional surgeries
* BMI ≤ 39 kg/m2
* If biologically female, not pregnant or planning to become pregnant over the study
* If biologically male, either sterile or using acceptable form of birth control
* Be willing and able to complete study procedures
Exclusion Criteria:
* Has previously undergone unilateral simple bunionectomy.
* Has a planned concurrent surgical procedure
* Has a concurrent painful condition that may require analgesic treatment during the study period or may confound postsurgical pain assessments
* Has a history or clinical manifestation of significant medical, neuropsychiatric, or other condition that could preclude or impair study participation or interfere with study assessments.
* Has a history of malignant hyperthermia or glucose-6-phosphate dehydrogenase deficiency.
* Has history or evidence of impaired liver function (e.g., alanine aminotransferase \[ALT\] \> 3 × upper limit of normal \[ULN\] or total bilirubin \> 2 × ULN), active hepatic disease, or cirrhosis.
* Has history or evidence of impaired renal function (e.g., creatinine \> 1.5 × ULN).
* Has a history of malignancy in the past year
* Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months